ORANGE COUNTY, Calif., May 18 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC), a leading developer, manufacturer and marketer of products that simplify, automate and innovate complex biomedical testing, announced today the pricing of its senior notes offering of:
This offering is being made pursuant to an effective shelf registration statement on file with the Securities and Exchange Commission and is expected to close May 21, 2009, subject to customary conditions. Citigroup Global Markets Inc., J.P. Morgan Securities Inc. and Morgan Stanley & Co. Incorporated are acting as active joint book-running managers for the offering.
Beckman Coulter expects to use the net proceeds from this offering of approximately $495 million to finance a portion of the acquisition price for the diagnostic systems portion of Olympus Corporation's Life Science business and for general corporate purposes. Pending the application of the net proceeds, Beckman Coulter plans to invest the net proceeds in U.S. government obligations, bank deposits or in other secure, short-term investments.
Certain statements in this news release may be deemed to include forward-looking statements, such as statements that relate to this offering and whether Beckman Coulter will consummate this offering. Forward-looking statements are typically identified by words or phrases, such as "believe," "expect," "anticipate," "intend," "estimate," "may increase," "may fluctuate," "plan," "goal," "target," "strategy," and similar expressions or future or conditional verbs such as "may," "will," "should," "would," and "could." These statements are based on current expectations, forecasts and assumptions and are subject to a number of risks and uncertainties. Actual results could differ materially from those anticipated by these forward-looking statements as a result of a number of factors, including economic, market and monetary policy risks; operational risks; investment performance, fiduciary, and asset services risks; credit risks; liquidity risks; holding company risks; regulation risks; litigation risks; tax and accounting risks; strategic and competitive risks; and reputation risks. For a further list and description of risks and uncertainties associated with Beckman Coulter's business, see reports filed by Beckman Coulter with the Securities and Exchange Commission, including the "Risk Factors" section in the most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the Securities and Exchange Commission. Beckman Coulter disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
This press release is neither an offer to sell nor a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The offering of these securities will be made only by means of a prospectus and related prospectus supplements. When available, copies of the prospectus and related prospective supplements may be obtained by calling Citigroup Global Markets Inc. toll-free at 1-877-858-5407, by mailing J.P. Morgan Securities Inc., Investment Grade Syndicate Desk, 270 Park Ave, New York, NY 10017, or by mailing Morgan Stanley & Co. Incorporated, Prospectus Department, 1585 Broadway, New York, NY 10036 or calling toll-free at 1-866-718-1649.
About Beckman Coulter
Beckman Coulter, Inc., based in Fullerton, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care.
Contact: Cynthia Skoglund, (714) 773-7620 Manager, Investor Relations
Copyright©2009 PR Newswire.
All rights reserved